Merck completed the acquisition of Imago BioSciences for $1.35bn.

Merck, a science and technology company, completed the acquisition of Imago BioSciences, a clinical-stage biopharmaceutical company, for $1.35bn. “We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve. This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology," Robert M. Davis, Merck President and CEO.